http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011516606-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00 |
| filingDate | 2008-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2011-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2011516606-A |
| titleOfInvention | Methods and pharmaceutical compositions for obtaining plasma progesterone concentrations required for various therapeutic indices |
| abstract | The present invention provides methods and pharmaceutical compositions for obtaining plasma progesterone concentrations in humans and for maintaining plasma progesterone concentrations at 42-3.5 ng / mL and peak progesterone concentrations (Cmax) at 12-42 ng / mL for 8 days The invention relates to the development of methods and pharmaceutical compositions wherein the progesterone concentration is sufficient for use in various therapeutic options where necessary. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021501343-A |
| priorityDate | 2008-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 23.